RS-1

Catalog No.S8234 Batch:S823401

Technical Data

Formula	C₂₀H₁₆Br₂N₂O₃S
Molecular Weight	524.23	CAS No.	312756-74-4
Solubility (25°C)*	In vitro	DMSO	100 mg/mL (190.75 mM)
		Water	Insoluble
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.

Targets

RAD51 ^[1]

In vitro

RS-1 stimulates the binding of hRAD51 to ssDNA. Low-micromolar concentrations of this small molecule enhance DNA binding and result in longer protein–DNA complex lengths. In addition, RS-1 stabilizes the active form of hRAD51 filaments and this is reflected in an enhanced strand assimilation activity^[1]. RS-1 enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo^[2].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Early-passage neonatal human dermal fibroblasts Concentrations 1-7.5 μM Incubation Time 24 h Method Early-passage neonatal human dermal fibroblasts were maintained in Medium 106 supplemented with low serum growth supplement. Cell-survival experiments were performed using a sulforhodamine B assay. Cells are incubated for 24 h in cisplatin with or without RS-1 and are subsequently incubated for an additional 6 days in normal media lacking both agents. Sulforhodamine B-stained cells are quantified with a Synergy plate reader.

Cell Assay:^{^[1]}

Cell lines
Early-passage neonatal human dermal fibroblasts
Concentrations
1-7.5 μM
Incubation Time
24 h
Method
Early-passage neonatal human dermal fibroblasts were maintained in Medium 106 supplemented with low serum growth supplement. Cell-survival experiments were performed using a sulforhodamine B assay. Cells are incubated for 24 h in cisplatin with or without RS-1 and are subsequently incubated for an additional 6 days in normal media lacking both agents. Sulforhodamine B-stained cells are quantified with a Synergy plate reader.

References

Selleck's RS-1 has been cited by 2 publications

Generation of VEGF knock-in Cashmere goat via the CRISPR/Cas9 system [ Int J Biol Sci, 2021, 17(4):1026-1040]	PubMed: 33867826
Construction of Synthetic Nanobody Library in Mammalian Cells by dsDNA-Based Strategies* [ Chembiochem, 2021, 22(20):2957-2965]	PubMed: 34411391

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.